Alcoholism
Drug research and approvals for alcoholism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 212 studies of alcoholism are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 212
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological,…NCT07925281 · Not reported · Université Catholique de Louvain · starts Nov 2, 2026
- Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With…NCT07844720 · Phase 2 · Institut National de la Santé Et de la Recherche Médicale, France · starts Nov 2, 2026
- Greek Connections StudyNCT07839026 · Not applicable · University of Washington · starts Sep 1, 2026
- Exercise Training Decreases Alcohol Consumption and Tissue Injury by an FGF21-dependent MechanismNCT07824089 · Not applicable · The Cleveland Clinic · starts Oct 25, 2026
- Imaging Mitochondrial Complex-I in Alcohol Use DisorderNCT07825818 · Early Phase 1 · Rajesh Narendran · starts Sep 30, 2026
- HD-tACS for Alcohol Use DisorderNCT07808190 · Not applicable · Shanghai Mental Health Center · starts Sep 15, 2026
- Sensory and Physical Reactions to Beverage CuesNCT07788716 · Not applicable · University of Texas Southwestern Medical Center · starts Oct 1, 2026
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesNCT07772960 · Phase 1 · Yale University · starts Oct 1, 2026
- TRIS: Contingency Management App for Alcohol Use DisorderNCT07735585 · Not applicable · University of Sao Paulo General Hospital · starts Feb 19, 2026
Approved 6
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- AcamprosateGlutamate [NMDA] receptor antagonist
- NalmefeneMu opioid receptor antagonist
- DisulfiramAldehyde dehydrogenase inhibitor
- ChlordiazepoxideGABA-A receptor; anion channel positive allosteric modulator
- DoxepinNorepinephrine transporter inhibitor
Phase 3 12 of 20
- OxytocinOxytocin receptor agonist
- TopiramateCarbonic anhydrase II inhibitor
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
- Alcohol
- BaclofenGABA-B receptor agonist
- VareniclineNeuronal acetylcholine receptor; alpha4/beta2 agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- GabapentinVoltage-gated calcium channel modulator
- ZonisamideSodium channel alpha subunit blocker
- PrazosinAdrenergic receptor alpha-1 antagonist
- AripiprazoleDopamine D2 receptor partial agonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
Phase 2 12 of 57
- PsilocybinSerotonin 2a (5-HT2a) receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- AcetylcysteineGlutathione precursor
- MifepristoneGlucocorticoid receptor antagonist
- SuvorexantOrexin receptor antagonist
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- SemaglutideGlucagon-like peptide 1 receptor agonist
- SertralineSerotonin transporter inhibitor
- AtomoxetineNorepinephrine transporter inhibitor
- GuanfacineAdrenergic receptor alpha-2 agonist
- DoxazosinAdrenergic receptor alpha-1 antagonist
- PregabalinVoltage-gated calcium channel modulator
Phase 1 or earlier 12 of 26
- PerampanelGlutamate receptor ionotropic AMPA antagonist
- DronabinolCannabinoid CB1 receptor agonist
- ORG-34517Glucocorticoid receptor antagonist
- GSK-1521498Mu opioid receptor antagonist
- MethylphenidateDopamine transporter inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- BrexanoloneGABA-A receptor; anion channel positive allosteric modulator
- SpironolactoneMineralocorticoid receptor antagonist
- Insulin humanInsulin receptor agonist
- ProbenecidSolute carrier family 22 member 6 inhibitor
- CaffeineAdenosine receptor antagonist
- TiagabineGABA transporter 1 inhibitor
How its trials ended
1,467 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 295 whose ending is known, 47% met their primary endpoint, 10% missed it and 43% stopped early.
- Completed, result not reported71949%
- Ongoing33022%
- Met its primary endpoint1389%
- Status unknown1238%
- Stopped: other or unclear836%
- Missed its primary endpoint302%
- Stopped: enrollment or feasibility201%
- Stopped: lack of efficacy111%
- Stopped: funding7<1%
- Stopped: sponsor or business decision6<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA